Cellectar Biosciences, Madison, said it will collaborate with Avicenna Oncology, of Basel, Switzerland, to develop drug prospects by combining their technologies.
The joint effort will employ Cellectar's drug delivery system along with Avicenna's anti-cancer small-molecule drug candidates to attack solid-tumor cancers, the companies said.
Financial terms of the collaboration have not been disclosed.
Cellectar is developing a series of treatments and diagnostic products aimed at a broad range of cancers.
Avicenna is focused on attacking drug-resistant cancers.
"We are very excited to combine our collective expertise to potentially provide new treatment options for patients," said Zaki Sellam, founder and CEO of Avicenna.